Switch theme
Sign up to access all valuation multiples
Ligand Pharmaceuticals Inc is a biopharmaceutical company focused on developing and acquiring technologies that aid in creating medicine. The company has partnerships and license agreements with various pharmaceutical and biotechnology companies. Ligand's business model is based on drug discovery, early-stage drug development, product reformulation, and partnerships. The company's revenue consists of three primary elements: royalties from commercialized products, license and milestone payments, and sale of its trademarked Captisol material.
1987
68
LTM Revenue $178M
LTM EBITDA $57.2M
$1.8B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Ligand Pharmaceuticals has a last 12-month revenue (LTM) of $178M and a last 12-month EBITDA of $57.2M.
In the most recent fiscal year, Ligand Pharmaceuticals achieved revenue of $167M and an EBITDA of $40.8M.
Ligand Pharmaceuticals expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Ligand Pharmaceuticals valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $178M | XXX | $167M | XXX | XXX | XXX |
| Gross Profit | $165M | XXX | $156M | XXX | XXX | XXX |
| Gross Margin | 93% | XXX | 93% | XXX | XXX | XXX |
| EBITDA | $57.2M | XXX | $40.8M | XXX | XXX | XXX |
| EBITDA Margin | 32% | XXX | 24% | XXX | XXX | XXX |
| EBIT | -$6.4M | XXX | $23.0M | XXX | XXX | XXX |
| EBIT Margin | -4% | XXX | 14% | XXX | XXX | XXX |
| Net Profit | -$2.7M | XXX | -$4.0M | XXX | XXX | XXX |
| Net Margin | -1% | XXX | -2% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Ligand Pharmaceuticals's stock price is $102.
Ligand Pharmaceuticals has current market cap of $2.0B, and EV of $1.8B.
See Ligand Pharmaceuticals trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $1.8B | $2.0B | XXX | XXX | XXX | XXX | $5.90 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Ligand Pharmaceuticals has market cap of $2.0B and EV of $1.8B.
Ligand Pharmaceuticals's trades at 10.6x EV/Revenue multiple, and 43.3x EV/EBITDA.
Equity research analysts estimate Ligand Pharmaceuticals's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Ligand Pharmaceuticals has a P/E ratio of -742.5x.
See valuation multiples for Ligand Pharmaceuticals and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $2.0B | XXX | $2.0B | XXX | XXX | XXX |
| EV (current) | $1.8B | XXX | $1.8B | XXX | XXX | XXX |
| EV/Revenue | 9.9x | XXX | 10.6x | XXX | XXX | XXX |
| EV/EBITDA | 30.9x | XXX | 43.3x | XXX | XXX | XXX |
| EV/EBIT | -274.8x | XXX | 76.8x | XXX | XXX | XXX |
| EV/Gross Profit | 10.7x | XXX | n/a | XXX | XXX | XXX |
| P/E | -742.5x | XXX | -489.0x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | 22.8x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialLigand Pharmaceuticals's last 12 month revenue growth is 17%
Ligand Pharmaceuticals's revenue per employee in the last FY averaged $2.5M, while opex per employee averaged $2.0M for the same period.
Ligand Pharmaceuticals's rule of 40 is 93% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Ligand Pharmaceuticals's rule of X is 75% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Ligand Pharmaceuticals and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 17% | XXX | 17% | XXX | XXX | XXX |
| EBITDA Margin | 32% | XXX | 24% | XXX | XXX | XXX |
| EBITDA Growth | 65% | XXX | -22% | XXX | XXX | XXX |
| Rule of 40 | 93% | XXX | 42% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 75% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $2.5M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $2.0M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 13% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 80% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Ligand Pharmaceuticals acquired XXX companies to date.
Last acquisition by Ligand Pharmaceuticals was XXXXXXXX, XXXXX XXXXX XXXXXX . Ligand Pharmaceuticals acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Ligand Pharmaceuticals founded? | Ligand Pharmaceuticals was founded in 1987. |
| Where is Ligand Pharmaceuticals headquartered? | Ligand Pharmaceuticals is headquartered in United States of America. |
| How many employees does Ligand Pharmaceuticals have? | As of today, Ligand Pharmaceuticals has 68 employees. |
| Who is the CEO of Ligand Pharmaceuticals? | Ligand Pharmaceuticals's CEO is Mr. Todd C. Davis. |
| Is Ligand Pharmaceuticals publicy listed? | Yes, Ligand Pharmaceuticals is a public company listed on NAS. |
| What is the stock symbol of Ligand Pharmaceuticals? | Ligand Pharmaceuticals trades under LGND ticker. |
| When did Ligand Pharmaceuticals go public? | Ligand Pharmaceuticals went public in 1995. |
| Who are competitors of Ligand Pharmaceuticals? | Similar companies to Ligand Pharmaceuticals include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Ligand Pharmaceuticals? | Ligand Pharmaceuticals's current market cap is $2.0B |
| What is the current revenue of Ligand Pharmaceuticals? | Ligand Pharmaceuticals's last 12 months revenue is $178M. |
| What is the current revenue growth of Ligand Pharmaceuticals? | Ligand Pharmaceuticals revenue growth (NTM/LTM) is 17%. |
| What is the current EV/Revenue multiple of Ligand Pharmaceuticals? | Current revenue multiple of Ligand Pharmaceuticals is 9.9x. |
| Is Ligand Pharmaceuticals profitable? | Yes, Ligand Pharmaceuticals is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Ligand Pharmaceuticals? | Ligand Pharmaceuticals's last 12 months EBITDA is $57.2M. |
| What is Ligand Pharmaceuticals's EBITDA margin? | Ligand Pharmaceuticals's last 12 months EBITDA margin is 32%. |
| What is the current EV/EBITDA multiple of Ligand Pharmaceuticals? | Current EBITDA multiple of Ligand Pharmaceuticals is 30.9x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
